NexGel Inc Common Stock Q3 2025 Earnings Recap

NXGL Q3 2025 November 12, 2025

Get alerts when NXGL reports next quarter

NEXGEL reported stable revenue of $2.9 million in Q3 2025 with improved gross profit margins and a narrowing adjusted EBITDA loss, reflecting operational efficiencies and strong demand in contract manufacturing.

Earnings Per Share Beat

$-0.08 vs $-0.09 est.

+11.1% surprise

Revenue Miss

2934000 vs 3240000 est.

-9.4% surprise

Market Reaction

1-Day -11.4%

5-Day -19.3%

30-Day -30.7%

See NXGL alongside your other holdings

Add to your portfolio — free

Key Takeaways

Contract manufacturing revenue reached $907,000, supported by strong partnerships, particularly with Cintas for wound care kits.
Adjusted EBITDA loss narrowed to $354,000, showing improvement from previous quarters.
Consumer brand segment remains stable, with new product launches anticipated to drive sales growth in Q4, including Silly George's lip gloss and Kenco Derm's eczema solutions.
Strategic partnership with Stada expanded to include new product launches aimed at the North American market, backed by significant non-dilutive financing.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NXGL on AllInvestView.